(2R)-2-(甲氧基甲基)吡咯烷盐酸盐 | 121817-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (2R)-2-(甲氧基甲基)吡咯烷盐酸盐
• 中文别名: (R)-2-甲氧甲基吡咯烷盐酸盐
• 英文名称: (R)-2-(methoxymethyl)pyrrolidine hydrochloride
• 英文别名: (2R)-2-(methoxymethyl)pyrrolidine;hydrochloride
• CAS: 121817-72-9
• 化学式: C₆H₁₃NO*ClH
• 分子量: 151.636
• InChiKey: QTMPYFZNWHQZAZ-FYZOBXCZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.81
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (2R)-2-(甲氧基甲基)吡咯烷盐酸盐 在 potassium hypochlorite 、 potassium hydroxide 作用下， 以 水 为溶剂， 反应 12.0h， 生成 1-氨基-2-（甲氧基甲基）-吡咯
  参考文献：
  名称：

  (S)-(−)-1-AMINO-2-METHOXYMETHYLPYRROLIDINE (SAMP) AND (R)-(+)-1-AMINO-2-METHOXYMETHYLPYRROLIDINE (RAMP), VERSATILE CHIRAL AUXILIARIES

  摘要：

  DOI：

  10.15227/orgsyn.065.0173
• 作为产物：
  描述：

  D-脯氨醇 在 sodium hydride 、 potassium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.83h， 生成 (2R)-2-(甲氧基甲基)吡咯烷盐酸盐
  参考文献：
  名称：

  (S)-(−)-1-AMINO-2-METHOXYMETHYLPYRROLIDINE (SAMP) AND (R)-(+)-1-AMINO-2-METHOXYMETHYLPYRROLIDINE (RAMP), VERSATILE CHIRAL AUXILIARIES

  摘要：

  DOI：

  10.15227/orgsyn.065.0173

文献信息

• Structure guided design of a series of sphingosine kinase (SphK) inhibitors
  作者：Darin J. Gustin、Yihong Li、Matthew L. Brown、Xiaoshan Min、Mike J. Schmitt、Malgorzata Wanska、Xiaodong Wang、Richard Connors、Sheere Johnstone、Mario Cardozo、Alan C. Cheng、Shawn Jeffries、Brendon Franks、Shyun Li、Shanling Shen、Mariwil Wong、Holger Wesche、Guifen Xu、Timothy J. Carlson、Matthew Plant、Kurt Morgenstern、Karen Rex、Joanna Schmitt、Angela Coxon、Nigel Walker、Frank Kayser、Zhulun Wang

  DOI：10.1016/j.bmcl.2013.06.030

  日期：2013.8

  inhibition of both isoforms is likely required to block SphK dependent angiogenesis. A structure based approach was used to design and synthesize a series of SphK inhibitors resulting in the identification of the first potent inhibitors of both isoforms of human SphK. Additionally, to our knowledge, this series of inhibitors contains the only sufficiently potent inhibitors of murine SphK1 with suitable

  鞘氨醇-1-磷酸（S1P）信号在有丝分裂，细胞迁移和血管生成中起着至关重要的作用。鞘氨醇激酶（SphKs）催化鞘磷脂代谢中的关键步骤，从而导致S1P的产生。SphK有两种同工型，对SphK缺陷小鼠的观察表明，这两种同工型可以弥补彼此的损失。因此，可能需要抑制两种同工型才能阻断SphK依赖性血管生成。基于结构的方法用于设计和合成一系列SphK抑制剂，从而鉴定出人类SphK两种同工型的第一种有效抑制剂。此外，据我们所知，
• [EN] INHIBITORS OF THE MENIN-MLL INTERACTION<br/>[FR] INHIBITEURS DE L'INTERACTION MÉNINE-MLL
  申请人：SYNDAX PHARMACEUTICALS INC

  公开号：WO2022241265A1

  公开（公告）日：2022-11-17

  The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

  本公开涉及公式（0）的抑制剂，或其立体异构体或其药学上可接受的盐，用于抑制Menin与MLL和MLL融合蛋白的相互作用，以及含有它们的制药组合物，并将其用于治疗由Menin-MLL相互作用介导的癌症和其他疾病。
• Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists
  作者：Zhaohui Yang、Xuan Li、Haikuo Ma、Jiyue Zheng、Xuechu Zhen、Xiaohu Zhang

  DOI：10.1016/j.bmcl.2013.11.051

  日期：2014.1

  We have previously reported a series of 2,4,6-trisubstituted pyrimidines as potent A(2A) receptor antagonists. The leading compounds often feature a potentially labile acetamide functional group which tends to hydrolyze under acidic conditions. Here we report the replacement of the acetamide functional group with bioisosteres. This effort led us to a new series of adenosine A(2A) receptor antagonists with improved potency and chemical stability. (C) 2013 Elsevier Ltd. All rights reserved.
• Optimization of 6-Heterocyclic-2-(1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(pyridin-2-yl)pyrimidin-4-amine as Potent Adenosine A_2A Receptor Antagonists for the Treatment of Parkinson’s Disease
  作者：Jiyue Zheng、Zhaohui Yang、Xuan Li、Linlang Li、Haikuo Ma、Meiyu Wang、Hongjian Zhang、Xuechu Zhen、Xiaohu Zhang

  DOI：10.1021/cn5000716

  日期：2014.8.20

  Parkinson's disease is a neurodegenerative disease characterized by the motor symptoms of bradykinesia, tremor, and rigidity. Current therapies are based mainly on dopaminergic replacement strategies by administration of either dopamine agonists or dopamine precursor levodopa (L-Dopa). These treatments provide symptomatic relief without slowing or stopping the disease progression, and long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinisia. Unfortunately, there had been few novel treatments developed in the past decades. Among nondopaminergic strategies for the treatment of Parkinson's disease, antagonism of the adenosine A2A receptor has emerged to show great potential. Here we report the optimization of a new chemical scaffold, which achieved exceptional receptor binding affinity and ligand efficiency against adenosine A2A receptor. The leading compounds demonstrated excellent efficacy in the haloperidol induced catalepsy model for Parkinson's disease.
• Application of Chiral Transfer Reagents to Improve Stereoselectivity and Yields in the Synthesis of the Antituberculosis Drug Bedaquiline
  作者：Juliana M. S. Robey、Sanjay Maity、Sarah L. Aleshire、Angshuman Ghosh、Ajay K. Yadaw、Subho Roy、Sarah Jane Mear、Timothy F. Jamison、Gopal Sirasani、Chris H. Senanayake、Rodger W. Stringham、B. Frank Gupton、Kai O. Donsbach、Ryan C. Nelson、Charles S. Shanahan

  DOI：10.1021/acs.oprd.3c00287

  日期：2023.11.17